Last updated on April 2019

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)


Brief description of study

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Clinical Study Identifier: NCT02704403

Find a site near you

Start Over

H pital Beaujon

Clichy, France
0.07miles
  Connect »

H pital Cochin

Paris, France
5.14miles
  Connect »

H pital Saint-Antoine

Paris, France
7.59miles
  Connect »

H pital Antoine-B cl re

Clamart, France
8.06miles
  Connect »

H pital Paul Brousse

Villejuif, France
8.21miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.